Pharmacovigilance – News and Features

Obesity is highly prevalent among patients with CVD and significantly impacts both the course and prognosis of the condition while contributing to an increased risk of morbidity.

Researchers have developed MS-41, an innovative anti-cancer degrader. This compound targets and degrades the ENL protein, crucial for MLL-rearranged leukemia in infants.

A new study has discovered that natural killer cells instinctively recognize and attack a protein that drives cancer growth. This feature could be exploited to develop new and less invasive forms of treatment.

The University of Calgary is testing probenecid, a drug for gout, to alleviate opioid withdrawal symptoms. Researchers found that probenecid reduces withdrawal pain in rodents by disrupting abnormal brain-spinal cord communication.

A study shows psilocybin and SSRIs affect brain dynamics differently in treating depression. Psilocybin induces a "flattening" of hierarchical brain structures, while SSRIs enhance hierarchical reorganization.

Dr. David Bending discusses his research interests and experience as an LGBTQIA+ immunologist. He offers advice for others beginning a career in STEMM and highlights the importance of LGBTQIA+ representation.

Study suggests that high doses of psilocybin appears to have a similar effect on depressive symptoms as the selective serotonin reuptake inhibitor escitalopram.

Research shows that an investigational drug significantly reduces the frequency and severity of hot flashes associated with menopause while improving women’s sleep and quality of life.

Harvard researchers found that donepezil, an FDA-approved Alzheimer's drug, can induce a hibernation-like state in tadpoles, potentially providing crucial time to treat severe injuries in emergency settings.

A study reveals that 20% of chronic cough patients are prescribed opioid-containing cough suppressants, with Medicaid and older patients more likely to receive these drugs.